VC
DSGN icon

Vivo Capital’s Design Therapeutics DSGN Stock Holding History

Vivo Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Hold
1,612,903
– – 2.13% 20
2026
Q1 		$17.2M Hold
1,612,903
– – 1.43% 25
2025
Q4 		$15.1M Buy
+1,612,903
New +$12.6M 0.98% 29
2022
Q3 		– Sell
-476,589
Closed -$6.67M – 52
2022
Q2 		$6.67M Hold
476,589
– – 0.67% 32
2022
Q1 		$7.7M Sell
476,589
-54,402
-10% -$833K 0.53% 35
2021
Q4 		$11.4M Hold
530,991
– – 0.69% 34
2021
Q3 		$7.8M Hold
530,991
– – 0.35% 45
2021
Q2 		$10.6M Hold
530,991
– – 0.46% 39
2021
Q1 		$15.9M Buy
+530,991
New +$17.9M 0.56% 35

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

Vivo Capital's DSGN Position: Q2 2026 in Review

Vivo Capital held its Design Therapeutics (DSGN) position steady in Q2 2026 at 1,612,903 shares worth $23.3M. The position accounts for 2.13% of the portfolio, ranked #20.

Vivo Capital first reported a position in DSGN in Q1 2021 and has held it in 9 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Vivo Capital held 1,612,903 shares of Design Therapeutics worth $23.3M as of Q2 2026.
  • Vivo Capital left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up 2.13% of Vivo Capital's portfolio in Q2 2026, its #20 holding.
  • Vivo Capital first reported a position in Design Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.